{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:05Z","timestamp":1767707525104},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,23]]},"DOI":"10.7759\/cureus.60946","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:29:31Z","timestamp":1716499771000},"source":"Crossref","is-referenced-by-count":1,"title":["Adult-Onset Still's Disease Following COVID-19 Infection in a Patient Receiving Nirmatrelvir\/Ritonavir: A Case Report"],"prefix":"10.7759","author":[{"given":"Georges","family":"El Hasbani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres I","family":"Applewhite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Scheuing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawena","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19. (2020). Accessed. May 22, 2024: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu B","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021, 19:141-54. 10.1038\/s41579-020-00459-7","journal-title":"Nat Rev Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934492","article-title":"COVID-19 and the immune system","volume":"69","author":"Paces J","year":"2020","unstructured":"Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020, 69:379-88. 10.33549\/physiolres.934492","journal-title":"Physiol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu J","year":"2023","unstructured":"Liu J, Pan X, Zhang S, et al.. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023, 33:100694. 10.1016\/j.lanwpc.2023.100694","journal-title":"Lancet Reg Health West Pac"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.03.008","article-title":"The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives","volume":"27","author":"Boechat JL","year":"2021","unstructured":"Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives. Pulmonology. 2021, 27:423-37. 10.1016\/j.pulmoe.2021.03.008","journal-title":"Pulmonology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221014","article-title":"Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases","volume":"50","author":"Gerolymatou N","year":"2023","unstructured":"Gerolymatou N, Bakasis AD, Voulgari PV, Vlachoyiannopoulos PG. Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2023, 50:1078-81. 10.3899\/jrheum.221014","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou P","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021, 51:858-74. 10.1016\/j.semarthrit.2021.06.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref8","article-title":"On a form of chronic joint disease in children","volume":"80","author":"Still GF","year":"1897","unstructured":"Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897, 80:47-60.9.","journal-title":"Med Chir Trans"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist E","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018, 14:603-18. 10.1038\/s41584-018-0081-x","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic PA","year":"2014","unstructured":"Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis Rheumatol. 2014, 66:1405-13. 10.1002\/art.38615","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00992-2","article-title":"COVID-19 and the role of cytokines in this disease","volume":"30","author":"Hasanvand A","year":"2022","unstructured":"Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022, 30:789-98. 10.1007\/s10787-022-00992-2","journal-title":"Inflammopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100996","article-title":"An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"38","author":"Dav\u00ec S","year":"2011","unstructured":"Dav\u00ec S, Consolaro A, Guseinova D, et al.. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011, 38:764-8. 10.3899\/jrheum.100996","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane G","year":"2016","unstructured":"Giancane G, Minoia F, Dav\u00ec S, Bracciolini G, Consolaro A, Ravelli A. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016, 7:467. 10.3389\/fphar.2016.00467","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00402-z","article-title":"Reasons for initiating canakinumab among patients with systemic juvenile idiopathic arthritis and adult-onset Still's disease in the U.S. real-world settings","volume":"9","author":"Hur P","year":"2022","unstructured":"Hur P, Yi E, Ionescu-Ittu R, et al.. Reasons for initiating canakinumab among patients with systemic juvenile idiopathic arthritis and adult-onset Still's disease in the U.S. real-world settings. Rheumatol Ther. 2022, 9:265-83. 10.1007\/s40744-021-00402-z","journal-title":"Rheumatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02651-3","article-title":"Increased incidence of adult-onset Still's disease in association with COVID-19 vaccination and SARS-CoV-2 infection","volume":"18","author":"Gottschalk MN","year":"2023","unstructured":"Gottschalk MN, Heiland M, Nahles S, Preissner R, Petri WA, Wendy S, Preissner S. Increased incidence of adult-onset Still's disease in association with COVID-19 vaccination and SARS-CoV-2 infection. Orphanet J Rare Dis. 2023, 18:50. 10.1186\/s13023-023-02651-3","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06124-z","article-title":"Two flares of Still's disease after two doses of the ChAdOx1 vaccine","volume":"41","author":"Roongta R","year":"2022","unstructured":"Roongta R, Mondal S, Haldar S, Kumar MS, Ghosh A. Two flares of Still's disease after two doses of the ChAdOx1 vaccine. Clin Rheumatol. 2022, 41:1591-6. 10.1007\/s10067-022-06124-z","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.21.22276724","article-title":"COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022","author":"Wang L","year":"2022","unstructured":"Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. medRxiv. 2022. 10.1101\/2022.06.21.22276724"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1179547621996306","article-title":"Diagnosis of adult onset Still's disease in a patient who has recovered from coronavirus-19","volume":"14","author":"Alshablan A","year":"2021","unstructured":"Alshablan A, Jabbad R, Tayeb S, et al.. Diagnosis of adult onset Still's disease in a patient who has recovered from coronavirus-19. Clin Med Insights Case Rep. 2021, 14:1179547621996306. 10.1177\/1179547621996306","journal-title":"Clin Med Insights Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00072-2","article-title":"First manifestation of adult-onset Still's disease after COVID-19","volume":"3","author":"Bamidis AD","year":"2021","unstructured":"Bamidis AD, Koehler P, di Cristanziano V, et al.. First manifestation of adult-onset Still's disease after COVID-19. Lancet Rheumatol. 2021, 3:e319-21. 10.1016\/S2665-9913(21)00072-2","journal-title":"Lancet Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.24911\/ejmcr\/173-1613255228","article-title":"Adult-onset Still\u2019s disease possibly consequent to asymptomatic COVID-19","volume":"5","author":"Ib\u00e1\u00f1ez P","year":"2021","unstructured":"Ib\u00e1\u00f1ez P, Iniesta A, Robles A, et al.. Adult-onset Still\u2019s disease possibly consequent to asymptomatic COVID-19. Eur J Med Case Rep. 2021, 5:218-21. 10.24911\/ejmcr\/173-1613255228","journal-title":"Eur J Med Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/11795441231161640","article-title":"An unforeseen outcome of COVID-19: the triggering of adult-onset Still's disease","volume":"16","author":"Alzuhaily H","year":"2023","unstructured":"Alzuhaily H, Mohamad S, Alsalloum L, Al-Sayed S. An unforeseen outcome of COVID-19: the triggering of adult-onset Still's disease. Clin Med Insights Arthritis Musculoskelet Disord. 2023, 16:11795441231161640. 10.1177\/11795441231161640","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/248223-adult-onset-stills-disease-following-covid-19-infection-in-a-patient-receiving-nirmatrelvirritonavir-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:29:35Z","timestamp":1716499775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/248223-adult-onset-stills-disease-following-covid-19-infection-in-a-patient-receiving-nirmatrelvirritonavir-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.60946","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}